[Comment] Body composition during major incretin-based weight loss
We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide in people with obesity but without diabetes.1 In people with type 2 diabetes, weight loss seems to be somewhat lower, at 8–9% with semaglutide and 11–13% […]
Liraglutide May Reduce Migraine Burden in Adults With Obesity, Migraine
MONDAY, June 30, 2025 — For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and Migraine Disability Assessment (MIDAS) scores, according to a study presented at the 11th Congress…